請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70360
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡克嵩(Keh-Sung Tsai),楊偉勛(Wei-Shiung Yang) | |
dc.contributor.author | Wei-Yih Chiu | en |
dc.contributor.author | 邱偉益 | zh_TW |
dc.date.accessioned | 2021-06-17T04:26:30Z | - |
dc.date.available | 2023-09-04 | |
dc.date.copyright | 2018-09-04 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-14 | |
dc.identifier.citation | Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005 Dec 1;23(34):8580-7.
Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, Voinea-Griffin AE, Group CC, Beadnell S, Craig RG, et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res. 2011 Apr;90(4):439-44. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013 Feb;19(2):179-92. Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004 Sep;44(9):951-65. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int. 2004 Jun;15(6):423-33. Bellido T, Plotkin LI, Bruzzaniti A. Chapter 2 - Bone Cells. Basic and Applied Bone Biology. 2014:27-45. Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol Pathol. 1995 Mar-Apr;23(2):115-23. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer. 2012 Nov 6;107(10):1665-71. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996 Dec 7;348(9041):1535-41. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer. 2006 May;14(5):408-18. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011 Feb;26(2):229-38. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003 May 15;423(6937):337-42. Burr DB, Akkus O. Chapter 1 - Bone Morphology and Organization. Basic and Applied Bone Biology. 2014:3-25. Chen S, Lee BH, Bae Y. Notch signaling in skeletal stem cells. Calcif Tissue Int. 2014 Jan;94(1):68-77. Chen YC, Chen P, Wu YR, Shie SS, Chen ST, Lee-Chen GJ, Chen CM. Protein kinase Ceta polymorphism and the susceptibilities to intracerebral hemorrhage in the Taiwan population. Neurosci Lett. 2012 Oct 24;528(2):170-3. Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. J Clin Endocrinol Metab. 2014 Aug;99(8):2729-35. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003 Jun 25;289(24):3243-53. Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011 Jul;49(1):42-9. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet. 2005 44(6):551-70. Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell ... and more. Endocr Rev. 2013 Oct;34(5):658-90. Day TF, Yang Y. Wnt and hedgehog signaling pathways in bone development. J Bone Joint Surg Am. 2008 Feb;90 Suppl 1(19-24. Delrieu O, Bowman C. Visualizing gene determinants of disease in drug discovery. Pharmacogenomics. 2006 Apr;7(3):311-29. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993 Dec;14(6):690-709. Denney W, Duvvuri S, Buckeridge C. Simple, Automatic Noncompartmental Analysis: The PKNCA R Package. Journal of Pharmacokinetics and Pharmacodynamics. 2015 42(S1):11-107, S65. Devlin B, Roeder K, Wasserman L. Genomic control, a new approach to genetic-based association studies. Theor Popul Biol. 2001 Nov;60(3):155-66. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008 Sep;83(9):1032-45. Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. Fan CT, Lin JC, Lee CH. Taiwan Biobank: a project aiming to aid Taiwan's transition into a biomedical island. Pharmacogenomics. 2008 Feb;9(2):235-46. Feldstein AC, Black D, Perrin N, Rosales AG, Friess D, Boardman D, Dell R, Santora A, Chandler JM, Rix MM, et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res. 2012 May;27(5):977-86. Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, et al. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int. 2002 Dec;13(12):971-9. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995 Sep;58(3):288-98. Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med. 2010 May 13;362(19):1848-9. Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010 Jul;122(1):181-8. Gural RP, Chungi VS, Shrewsbury RP, Dittert LW. Dose-dependent absorption of disodium etidronate. J Pharm Pharmacol. 1985 Jun;37(6):443-5. Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. Bone. 2014 Feb;59(44-52. Hansen PJ, Knitschke M, Draenert FG, Irle S, Neff A. Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment - a grossly underestimated risk? Clin Oral Investig. 2013 Nov;17(8):1829-37. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, 3rd, Brown J, Eriksen EF, Hoseyni MS, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999 Oct 13;282(14):1344-52. Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, Kondou E, Takeda D, Kojima Y, Sato S, et al. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int. 2017 Aug;28(8):2465-73. Hasegawa T, Ri S, Umeda M, Komatsubara H, Kobayashi M, Shigeta T, Yoshitomi I, Ikeda H, Shibuya Y, Asahina I, et al. The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy. J Craniomaxillofac Surg. 2013 Oct;41(7):558-63. Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res. 1992 Jan;7(1):65-72. Hoggart CJ, Parra EJ, Shriver MD, Bonilla C, Kittles RA, Clayton DG, McKeigue PM. Control of confounding of genetic associations in stratified populations. Am J Hum Genet. 2003 Jun;72(6):1492-504. Hong JW, Nam W, Cha IH, Chung SW, Choi HS, Kim KM, Kim KJ, Rhee Y, Lim SK. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos Int. 2010 May;21(5):847-53. Huang W, Yang S, Shao J, Li YP. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci. 2007 May 1;12(3068-92. Kanis JA, Melton LJ, 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994 Aug;9(8):1137-41. Katz J, Gong Y, Salmasinia D, Hou W, Burkley B, Ferreira P, Casanova O, Langaee TY, Moreb JS. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2011 Jun;40(6):605-11. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015 Jan;30(1):3-23. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Lentle B, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009 Mar;36(3):478-90. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012 Jul;97(7):2272-82. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007 Oct;22(10):1479-91. Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, et al. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab. 2006 24(5):405-13. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006 May;116(5):1202-9. Kubo M, Hata J, Ninomiya T, Matsuda K, Yonemoto K, Nakano T, Matsushita T, Yamazaki K, Ohnishi Y, Saito S, et al. A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat Genet. 2007 Feb;39(2):212-7. Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, et al. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab. 2004 22(5):469-78. Kwok T, Choy TK, Kwok WL. Prevalence of bisphosphonate-related osteonecrosis of the jaw in Hong Kong. Hong Kong Med J. 2016 Feb;22 Suppl 2(S46-7. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996 Feb;18(2):75-85. Lin JH, Chen IW, deLuna FA. On the absorption of alendronate in rats. J Pharm Sci. 1994 Dec;83(12):1741-6. Lin TC, Yang CY, Kao Yang YH, Lin SJ. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos Int. 2014 May;25(5):1503-11. Lin YC, Pan WH. Bone mineral density in adults in Taiwan: results of the Nutrition and Health Survey in Taiwan 2005-2008 (NAHSIT 2005-2008). Asia Pac J Clin Nutr. 2011 20(2):283-91. Lo JC, Hui RL, Grimsrud CD, Chandra M, Neugebauer RS, Gonzalez JR, Budayr A, Lau G, Ettinger B. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone. 2016 Apr;85(142-7. Lo JC, O'Ryan F, Yang J, Hararah MK, Gonzalez JR, Gordon N, Silver P, Ansfield A, Wang B, Go AS. Oral health considerations in older women receiving oral bisphosphonate therapy. J Am Geriatr Soc. 2011 May;59(5):916-22. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, Hutchinson M, Lathon PV, Sanchez G, Silver P, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010 Feb;68(2):243-53. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998 Apr;13(4):581-9. Marie PJ, Miraoui H, Severe N. FGF/FGFR signaling in bone formation: progress and perspectives. Growth Factors. 2012 Apr;30(2):117-23. Marini F, Tonelli P, Cavalli L, Cavalli T, Masi L, Falchetti A, Brandi ML. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front Biosci (Elite Ed). 2011 3(364-70. Matsuo K, Otaki N. Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adh Migr. 2012 Mar-Apr;6(2):148-56. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007 Mar;65(3):415-23. Meibohm B, Evans WE. Clinical pharmacodynamics and pharmacokinetics. Textbook of therapeutics: drug and disease management. 2006:1-30. Moreira MS, Katayama E, Bombana AC, Marques MM. Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue. a pilot study. Dent Traumatol. 2005 Dec;21(6):329-35. Nakai K, Tobinai M, Hashimoto J, Iida S, Kawanishi T. The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties. Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):139-47. Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H, et al. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporos Int. 2015 Nov;26(11):2685-93. Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A, Zavras AI. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist. 2012 17(2):279-87. NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001 Feb 14;285(6):785-95. Ott SM. What is the optimal duration of bisphosphonate therapy? Cleve Clin J Med. 2011 Sep;78(9):619-30. Pan W, Fann C, Wu J, Hung S, Hung Y, Chen Y, Hsu C, Liao C, Chen Y. Establishment of Taiwan Han Chinese Cell and Gene Bank: Comparing SNP profiles in MHC region with Caucasians. Am J Hum Genet. 2004 73(A1149. Pan WH, Fann CS, Wu JY, Hung YT, Ho MS, Tai TH, Chen YJ, Liao CJ, Yang ML, Cheng AT, et al. Han Chinese cell and genome bank in Taiwan: purpose, design and ethical considerations. Hum Hered. 2006 61(1):27-30. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst. 2011 Feb 2;103(3):232-40. Pillai G, Gieschke R, Goggin T, Barrett J, Worth E, Steimer JL. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. Int J Clin Pharmacol Ther. 2006 Dec;44(12):655-67. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999 May;36(5):315-28. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006 Aug;38(8):904-9. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. Am J Hum Genet. 2000 Jul;67(1):170-81. Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014 Apr;19(2):403-10. Reginster JY, Wilson KM, Dumont E, Bonvoisin B, Barrett J. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab. 2005 Sep;90(9):5018-24. Rivadeneira F, Makitie O. Osteoporosis and Bone Mass Disorders: From Gene Pathways to Treatments. Trends Endocrinol Metab. 2016 May;27(5):262-81. Rocha-Braz MG, Ferraz-de-Souza B. Genetics of osteoporosis: searching for candidate genes for bone fragility. Arch Endocrinol Metab. 2016 Aug;60(4):391-401. Ruggiero SL, Dodson TB. American Association of Oral and Maxillofacial Surgeons position Paper on Medication-Related Osteonecrosis of the Jaws- 2014 Update. J Oral Maxillofac Surg. 2014 Dec;72(12):2381-2. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, American Association of O, Maxillofacial S. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F, American Association of O, Maxillofacial S. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, Santamaria C, Rosinol L, de la Rubia J, Hernandez MT, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008 Oct 1;112(7):2709-12. Satten GA, Flanders WD, Yang Q. Accounting for unmeasured population substructure in case-control studies of genetic association using a novel latent-class model. Am J Hum Genet. 2001 Feb;68(2):466-77. Scheper M, Chaisuparat R, Cullen K, Meiller T. A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. Fibrogenesis Tissue Repair. 2010 3(6. Schwetz V, Pieber T, Obermayer-Pietsch B. The endocrine role of the skeleton: background and clinical evidence. Eur J Endocrinol. 2012 Jun;166(6):959-67. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc. 2009 Jan;140(1):61-6. Serizawa M, Nabika T, Ochiai Y, Takahashi K, Yamaguchi S, Makaya M, Kobayashi S, Kato N. Association between PRKCH gene polymorphisms and subcortical silent brain infarction. Atherosclerosis. 2008 Aug;199(2):340-5. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014 Jan;29(1):1-23. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010 Nov;25(11):2267-94. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int. 1999 10(3):183-92. Stewart TL, Ralston SH. Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol. 2000 Aug;166(2):235-45. Su N, Jin M, Chen L. Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models. Bone Res. 2014 2(14003. Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, Hughes PJ, Leach JW, Swenson KK, Gopalakrishnan R. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol. 2012 Aug;35(4):386-92. Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc. 2012 78(c85. Tsai K, Twu S, Chieng P, Yang R, Lee T. Prevalence of vertebral fractures in chinese men and women in urban Taiwanese communities. Calcif Tissue Int. 1996 Oct;59(4):249-53. Twiss IM, de Water R, den Hartigh J, Sparidans R, Ramp-Koopmanschap W, Brill H, Wijdeveld M, Vermeij P. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci. 1994 May;83(5):699-703. Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, et al. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab. 2005 23(5):382-8. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 1999 Feb 16;255(2):491-4. Vega D, Maalouf NM, Sakhaee K. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007 Dec;92(12):4514-21. Vestergaard P, Schwartz K, Rejnmark L, Mosekilde L, Pinholt EM. Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study. J Oral Maxillofac Surg. 2012 Apr;70(4):821-9. Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T. Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig. 2010 Feb;14(1):35-41. Wang CB, Lin CF, Liang WM, Cheng CF, Chang YJ, Wu HC, Wu TN, Leu TH. Excess mortality after hip fracture among the elderly in Taiwan: a nationwide population-based cohort study. Bone. 2013 Sep;56(1):147-53. Wein MN. Parathyroid Hormone Signaling in Osteocytes. JBMR Plus. 2018 2(1):22-30. Wu L, Shen Y, Liu X, Ma X, Xi B, Mi J, Lindpaintner K, Tan X, Wang X. The 1425G/A SNP in PRKCH is associated with ischemic stroke and cerebral hemorrhage in a Chinese population. Stroke. 2009 Sep;40(9):2973-6. Wu M, Chen G, Li YP. TGF-beta and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 2016 4(16009. Yamazaki T, Yamori M, Yamamoto K, Saito K, Asai K, Sumi E, Goto K, Takahashi K, Nakayama T, Bessho K. Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: a hospital-based cohort study in Japan. Bone. 2012 Nov;51(5):882-7. Yang J, Andre P, Ye L, Yang YZ. The Hedgehog signalling pathway in bone formation. Int J Oral Sci. 2015 Jun 26;7(2):73-9. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017 Jan;35(1):6-19. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010 Jul;28(4):365-83. Yu J, Pressoir G, Briggs WH, Vroh Bi I, Yamasaki M, Doebley JF, McMullen MD, Gaut BS, Nielsen DM, Holland JB, et al. A unified mixed-model method for association mapping that accounts for multiple levels of relatedness. Nat Genet. 2006 Feb;38(2):203-8. Zuo C, Huang Y, Bajis R, Sahih M, Li YP, Dai K, Zhang X. Osteoblastogenesis regulation signals in bone remodeling. Osteoporos Int. 2012 Jun;23(6):1653-63. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70360 | - |
dc.description.abstract | 背景
隨著老年人口不斷攀升,骨質疏鬆及其相關骨折的預防與治療,已是臺灣極重要的健康議題之一。雙磷酸鹽類藥物目前廣泛用於骨質疏鬆的治療與預防,然而對長期使用者,卻有造成顎骨壞死與非典型股骨骨折的風險。 一份來自美國南加州大學的研究指出,因骨鬆服用雙磷酸鹽引發顎骨壞死的病例中,多數是亞裔美國人,暗示在亞洲族群可能有較西方族群高顎骨壞死疑慮。然而,臺灣骨鬆病患接受雙磷酸鹽類藥物治療而併發顎骨壞死的風險仍是未知。要降低顎骨壞死的風險策略之一,便是在族群裡找尋併發顎骨壞死的危險因子。所以,我們此計畫的研究目的,一是分別藉由臺大醫院資料與全民健保資料庫,探查臺灣骨鬆病患接受雙磷酸類藥物治療而併發顎骨壞死的發生率與危險因子;二是找尋不同種族間,有不同雙磷酸鹽類藥物併發顎骨壞死發生率的可能機轉。 材料及方法 研究資料取自臺大醫院處方明細資料與臺灣全民健康保險承保抽樣歸人檔。考慮女性停經平均年齡與男性年老性骨鬆年齡,女性50歲以上或男性60歲以上,於研究區間開始使用阿侖磷酸(alendroante)或雷洛昔芬(raloxifene)的病患,分別收案為實驗組與對照組。在臺灣,此兩種藥物的健保給付規範是相同的,而且阿侖磷酸與雷洛昔芬也是臺灣口服骨鬆藥物的前兩名。此外,雷洛昔芬並未有顎骨壞死的個案被報告。在比較阿侖磷酸與雷洛昔芬兩組顎骨壞死的發生率時,我們只分析比較50歲以上女性的資料,因為雷洛昔芬並沒有治療男性骨鬆的支持證據。 雙磷酸鹽類藥物導致顎骨壞死的定義是,在曾經或正接受雙磷酸鹽類藥物而沒有顎面區放射治療過往史的病患,在顎面區出現骨暴露持續八週以上。在以臺大醫院為基礎的研究中,顎骨壞死的病例,是先搜尋由牙科醫師所下疑似牙槽骨發炎的個案,再逐一比對影像與病理紀錄確診。而在使用全民健保資料的研究中,為克服研究期間尚未有藥物併發顎骨壞死的特定診斷碼,所可能導致的錯誤歸類偏差(misclassification bias),透過由牙科醫師所下疑似牙槽骨發炎的診斷碼,隨後又有用來處理顎骨壞死的手術,只收集需要手術的顎骨壞死個案。 為探查亞洲與西方種族,在接受相同劑量劑型的雙磷酸鹽藥物後,是否藥物動力學指標(pharmacokinetic parameters)表現有所不同,我們向國際臨床試驗資料服務網申請利用口服伊班磷酸(ibandronate)一期臨床試驗 (Roche藥廠試驗代號BP16331與ML20793) 原始資料進行病人層級的次級分析。為了尋找顎骨壞死之風險對偶基因(risk allele),我們針對在台大醫院治療過的雙磷酸鹽類藥物導致顎骨壞死病患,在說明與知情同意後,收案進行全基因組關聯分析(genome-wide association study; GWAS)的研究。 結果 我們的研究結果顯示,骨質疏鬆病人服用雙磷酸鹽類藥物,與顎骨壞死的發生是有關聯的,且顎骨壞死的發生率會隨著累積使用時間的增加而增加。阿侖磷酸(alendroante)併發顎骨壞死的發生率,由臺大醫院的資料分析估計是每十萬人年分之283,而在使用全民健保資料的研究中則是每十萬人年分之262。在調整控制可能的干擾因素後,阿侖磷酸(alendroante)依舊是顎骨壞死的獨立危險因子,與雷洛昔芬(raloxifene)相較,風險率為7.42 [信賴區間1.02至54.09]。在骨質疏鬆病人服用阿侖磷酸(alendroante)的情況下,拔牙則會增加顎骨壞死9.6倍的風險,且無論藥物的累積使用時間長短都會增加。其他會增加阿侖磷酸(alendroante)併發顎骨壞死的獨立危險因子,還包括年紀大(65歲以上)、累積使用時間長(大於3年)、糖尿病、風濕性關節炎。 在同樣口服每月一次150毫克的伊班磷酸(ibandronate)進行藥物動力學及藥效分析,與歐洲人種相較,臺灣人有較高的藥物濃度-時間曲線面積(area under the concentration-time curve; AUC)及較大的骨再吸收抑制率-時間曲線面積(area under the antiresorptive effect-time curve; AUEC)。較高的藥物濃度-時間曲線面積(AUC),可能導因於較高的生體可用率(bioavailability),而這指標則受體型影響,台灣人的體型身高較西方的英國、比利時人矮小。在全基因組關聯分析研究中,我們最終收案了66位雙磷酸鹽類藥物併發顎骨壞死的骨鬆患者。初步結果顯示,protein kinase C-eta基因多形性(rs17098356)可能與顎骨壞死有關,而protein kinase C-eta與血管內皮生長因子(vascular endothelial growth factor; VEGF)訊息鏈有關。這部分的研究仍在進行,我們很快就將驗證這個發現。 結論 與西方人相較,台灣人服用雙磷酸鹽類藥物後,併發顎骨壞死的發生率較高。雙磷酸鹽類藥物併發顎骨壞死的危險因子,包括治療時間較長(大於3年)、拔牙、老年、糖尿病與風濕性關節炎。發生率高的原因可能包括台灣人體型較小,造成藥物生體可用率高,因此血液藥物濃度高、藥效較高。此外,某些基因也可能影響顎骨壞死的發生。 | zh_TW |
dc.description.abstract | (Background) With rapidly increasing number of elderly, osteoporosis and its associated fractures have become critical health issues in Taiwan. Bisphosphonates (BPs) are widely used for the treatment of osteoporosis. However, there has been concern about osteonecrosis of the jaw (ONJ) and atypical femoral fracture in the long-term users of BPs.
A retrospective study conducted at the University of Southern California demonstrated that most reported ONJ patients on oral alendronate as a treatment for osteoporosis were Asian Americans, raising concern about the higher prevalence of ONJ in the Asians versus Western populations after a bisphosphonate therapy. However, the frequency of ONJ among osteoporotic Taiwanese subjects exposed to BPs remains uncertain. One of the strategies to reduce the risk of ONJ is to identify potential contributing factors especially those unique to this Asian population. Therefore, the aims of our study were (1) to explore the incidence and risk factors of BP-related ONJ in osteoporotic patients in Taiwan by utilizing hospital-based data and nationwide health insurance database; and (2) to investigate the possible mechanisms accounting for the ethnic difference in ONJ incidence. (Methods) Data were retrieved from the pharmacy database at National Taiwan University Hospital and from Taiwan’s Longitudinal Health Insurance Database. Considering the mean age of menopause in women and the usual onset of senile osteoporosis in men, women aged 50 years or older or men aged 60 years or older who began taking alendronate or raloxifene during the study period were identified and as the exposure or control group, respectively. In Taiwan, regulations governing the insurance reimbursement for both agents are identical. Alendronate and raloxifene were the top two most commonly prescribed osteoporosis drugs in oral form. Besides, ONJ has not yet been reported with raloxifene. To compare the incidences of ONJ between alendronate and raloxifene groups, we analyzed only female patients aged 50 years or older due to the paucity of evidence to treat male osteoporosis with raloxifene. BP-related ONJ was defined as the presence of exposed bone in the maxillofacial region for more than 8 weeks in persons treated with a BP without radiotherapy to the jaws. ONJ cases were identified by a possible diagnosis codes for ONJ made by dentists and followed by confirmation with radiographic and pathological evidences in our hospital-based study. At the time of the analysis in the nationwide health insurance database, we ascertained only advanced ONJ cases required operative therapy through any dental surgery for ONJ following the diagnosis codes for ONJ made by dentists to overcome a potential misclassification bias resulting from no specific disease code available for drug-related ONJ To investigate whether the pharmacokinetic parameters are different between Asian and Western populations after receiving BP with a similar dosing formula, we utilized anonymised patient level data retrieved from two oral ibandronate phase 1 studies for secondary analysis (Roche sponsored studies, BP16331 & ML20793) through a consortium of clinical study data providers. To discover risk alleles/genes responsible for ONJ through genome-wide association study (GWAS), we prospectively enrolled osteoporotic patients with BP-related ONJ treated at National Taiwan University Hospital after obtaining informed consent. (Results) Our results support the association of ONJ with oral BP in osteoporotic patients. The incidence of ONJ increases with the duration of therapy. The estimated incidence rates of ONJ associated with alendronate were respectively 283 and 262/100,000 person-years in our hospital-based and nationwide population studies. After adjusting for the potential confounders, alendronate remains an independent predictor for ONJ occurrence (hazard ratio, 7.42 [1.02-54.09]) compared with raloxifene. Tooth extraction was associated with a 9.6-fold increased risk of ONJ among patients taking oral alendronate, independent of the duration of BP use. Other risk factors to the development of oral alendronate-related ONJ include advanced age (>= 65 years), drug duration (>= 3 years) and coexisting diabetes and rheumatoid arthritis. In pharmacokinetic study, Taiwanese subjects have higher pharmacokinetic area under the concentration-time curve (AUC) and subsequent pharmacodynamic area under the antiresorptive effect-time curve (AUEC) compared with European subjects after dosing with oral ibandronate of 150 mg per month. The higher pharmacokinetic area AUC may result from greater bioavailability, which was related to body height. For genetic study, we so far enrolled 66 BP-related ONJ osteoporotic patients to investigate the ONJ pathophysiology through GWAS. The preliminary data suggested a polymorphism (rs17098356) of the Protein Kinase C-eta in vascular endothelial growth factor (VEGF) signaling pathway as a risk allele for ONJ. The work is in progress and we will validate this finding in the near future. (Conclusion) The incidence of oral BP-related ONJ in Taiwanese population is higher than those reported in the Western populations. The risk factors to the occurrence of alendronate-related ONJ include longer drug duration (>= 3 years), antecedent tooth extraction, advanced age (>= 65 years), and coexisting diabetes and rheumatoid arthritis. The mechanisms of a higher incidence of alendronate-related ONJ in our Taiwanese population than the Europeans may include higher serum BP concentrations with higher subsequent antiresorptive effects resulting from greater bioavailability, which may be determined by shorter height of Taiwanese compared to the Europeans. In addition, risk genetic loci may give some contribution to the development of ONJ in this Asian population. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T04:26:30Z (GMT). No. of bitstreams: 1 ntu-107-D01421006-1.pdf: 2461441 bytes, checksum: a0fa711fc8db59a5a3479fe4e50f9d11 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | I. INTRODUCTION…………………………………………………….. P. 1
I-1. Introduction of Osteoporosis………………………………………. P. 1 I-1-1. Definition and diagnosis P. 1 I-1-2. Osteoporosis and its associated fractures are critical health issues in Taiwan P. 2 I-1-3. Overview of bone biology and osteoporosis pathophysiology P. 2 I-1-4. Genetic determinants of osteoporosis P. 8 I-1-5. Currently available drugs for osteoporosis in Taiwan P. 9 I-2. Bisphosphonates (BPs).……………………………………………. P. 10 I-2-1. Pharmacology of BPs P. 10 I-2-2. BPs: Role in clinical practice P. 12 I-2-3. Adverse effects of BPs: Osteonecrosis of the jaw (ONJ) P. 12 I-2-4. Adverse effects of BPs: Atypical femoral fracture (AFF) P. 13 I-3. The Possible Pathogenesis of ONJ…………………….………….. P. 14 I-3-1. Suppression of bone remodeling P. 15 I-3-2. Compromised epithelial barrier and host defense P. 15 I-3-3. Genetic predisposition of BP-related ONJ pathogenesis P. 16 I-4. The Specific Purposes of the Present Study………………………. P. 18 II. MATERIALS AND METHODS…………………………………….. P. 19 II-1. Hospital-based Cohort Study……………………………………. P. 19 II-1-1. Cohort identification and ONJ verification P. 19 II-1-2. Statistical analysis P. 19 II-2. Nationwide Population Study……………………………………. P. 20 II-2-1. Data source P. 20 II-2-2. Study design P. 21 II-2-3. Statistical analysis P. 23 II-3. Ethnic Difference in the Pharmacokinetics of 150 mg Oral Ibandronate………………………………………………………… P. 23 II-3-1. Data source P. 23 II-3-2. Study population P. 24 II-3-3. Pharmacokinetic and pharmacodynamic analyses P. 25 II-3-4. Data analysis P. 26 II-4. Pharmacogenomics in Osteoporotic Patients with BP-related ONJ… P. 26 II-4-1. Patients enrollment and sources of control samples P. 27 II-4-2. Genome-wide association study (GWAS) P. 28 III. RESULTS……………………………………………………………. P. 29 III-1. Hospital-based Cohort Study…………………………………….. P. 29 III-1-1. Risk factors associated with ONJ development P. 29 III-1-2. Alendronate leads to a higher incidence of ONJ compared to Raloxifene P. 30 III-2. Nationwide Population Study…………………………………….. P. 32 III-2-1. Alendronate was associated with a higher incidence of ONJ in osteoporotic patients P. 33 III-2-2. Tooth extractions increased the risk of ONJ P. 34 III-2-3. Tooth extractions increased the ONJ risk independent of the duration of alendronate therapy P. 35 III-3. Ethnic Difference in the Pharmacokinetics of 150mg Oral Ibandronate……………………….…………………….…………… P. 36 III-3-1. Pharmacokinetic measurements across two populations P. 36 III-3-2. Pharmacodynamic anti-resorptive effect across two populations P. 38 III-4. Pharmacogenomics in Osteoporotic Patients with BP-related ONJ... P. 39 III-4-1. A polymorphism of the Protein Kinase C-eta was identified to be associated with bisphosphonate-related ONJ P. 39 IV. DISCUSSIONS………………………………………………………… P. 41 IV-1. Hospital-based Cohort Study……………………………………… P. 41 IV-1-1. Differences in BP-related ONJ incidence in osteoporotic patients among ethnic populations P. 41 IV-1-2. Contributing factors of ONJ occurrence in osteoporotic Taiwanese subjects P. 42 IV-2. Nationwide Population Study……………………………………… P. 43 IV-2-1. Asian females have a greater risk of BP-related dentoskeletal events compared to white women P. 43 IV-2-2. The strength of the association between tooth extraction and ONJ in BP-treated osteoporotic patients P. 45 IV-2-3. Among osteoporotic patients exposed to alendronate, tooth extraction should be performed with caution irrespective of drug duration P. 46 IV-3. Ethnic Difference in the Pharmacokinetics of 150 mg Oral Ibandronate P. 47 IV-3-1. Difference in bioavailability of 150 mg oral ibandronate between European and Taiwanese postmenopausal women P. 47 IV-3-2. Body size influences the pharmacokinetics of oral ibandronate P. 49 IV-4. Pharmacogenomics in Osteoporotic Patients with BP-related ONJ… P. 51 V. PERSPECTIVES………………………………………………………. P. 53 VI. REFERENCES…………………………………………………………. P. 56 TABLES Table 1 WHO criteria for diagnosis of osteoporosis P. 71 Table 2 Genetic determinants of osteoporosis P. 72 Table 3 Currently available drugs for osteoporosis in Taiwan P. 76 Table 4 Staging criteria and treatment strategies for ONJ P. 77 Table 5 Risk factors for development of ONJ P. 78 Table 6 Genetic predisposition of bisphosphonate-related ONJ P. 79 Table 7 Possible diagnosis codes for ONJ in nationwide population study in nationwide population study P. 80 Table 8 Operative therapies to treat ONJ in nationwide population study in nationwide population study P. 81 Table 9 Clinical characteristics in patients taking alendronate without and with ONJ in hospital-based cohort study P. 82 Table 10 Risk factors for developing ONJ in patients receiving alendronate therapy in hospital-based cohort study P. 83 Table 11 Baseline characteristics before the use of Alendronate or Raloxifene in hospital-based cohort study P. 84 Table 12 Association between hazard rate and risk factors based on the multivariate Cox model in hospital-based cohort study P. 85 Table 13 Comparisons of the baseline characteristics in patients taking alendronate or raloxifene in nationwide population study P. 86 Table 14 Clinical characteristics of patients taking alendronate with and without ONJ in nationwide population study P. 87 Table 15 Risk factors for the development of ONJ in patients receiving alendronate in nationwide population study P. 88 Table 16 Patients characteristics across two populations in PK study of oral ibandronate P. 89 Table 17 Comparisons of the PK parameters across two populations P. 90 Table 18 Multiple linear regression using different anthropometric predictors for primary PK parameters P. 91 Table 19 Comparison of the area under the antiresorptive effect-time curve (AUEC) across two populations P. 93 Table 20 The incidence of bisphosphonate-related ONJ in osteoporotic patients among various ethnic populations P. 94 Table 21 Pharmacokinetic parameters of 150 mg oral ibandronate to different ethnic populations P. 95 FIGURES Figure 1 Important signal networks of osteoblast and osteoclast differentiation P. 96 Figure 2 Proposed mechanism for ONJ P. 98 Figure 3 Study design of nationwide population study P. 99 Figure 4 Study designs of the PK/PD study of oral ibandroante P. 100 Figure 5 Incidence of ONJ associated with oral alendronate by duration of drug therapy in hospital-based cohort study P. 101 Figure 6 Time to the onset of ONJ in patients receiving alendronate or raloxifene in hospital-based cohort study P. 102 Figure 7 Time to the onset of ONJ in patients receiving alendronate or raloxifene in nationwide population study P. 103 Figure 8 Tooth extraction increases the risk of ONJ independent of the duration of alendronate in nationwide population study P. 104 Figure 9 Mean serum concentration-time profiles after oral administration of 150mg ibandronate to Caucasian and Taiwanese postmenopausal women P. 105 Figure 10 Fraction of dose excreted in the urine following the first and third doses of oral ibandronate P. 106 Figure 11 The pharmacodynamic endpoint: The changes in bone turnover markers. P. 107 Figure 12 A polymorphism of the Protein Kinase C-eta was identified to be associated with bisphosphonate-related ONJ P. 108 APPENDIX: Publications in this period P. 109 | |
dc.language.iso | en | |
dc.title | 骨質疏鬆患者接受口服雙磷酸鹽類藥物併發顎骨壞死:流行病學、藥物動力學及藥物基因體學 | zh_TW |
dc.title | Oral Bisphosphonate-associated Osteonecrosis of the Jaws in Osteoporotic Subjects: Epidemiology, Pharmacokinetics and Pharmacogenomics | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 李正?(Jang-Jaer Lee),陳沛隆(Pei-Lung Chen),羅淑芬(Shue-Fen Luo),羅文良(Wen-Liang Lo) | |
dc.subject.keyword | 顎骨壞死,骨質疏鬆,雙磷酸鹽,藥物動力學,藥物基因體學, | zh_TW |
dc.subject.keyword | Osteonecrosis of the jaws,Osteoporosis,Bisphosphonate,Pharmacokinetics,Pharmacogenomics, | en |
dc.relation.page | 109 | |
dc.identifier.doi | 10.6342/NTU201803215 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 2.4 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。